Squalane

Within the SIRIAM Platform, Squalane is classified as a Regional Signature Component.

Unlike the Structural & Dermal Support Core, Release Core and Integration Core ingredients, Squalane is incorporated selectively into regional formulations according to their intended neurodermal objectives.

Within the SIRIAM formulation philosophy, Squalane serves as both a functional pharmaceutical excipient and a biologically compatible lipid. It contributes to dermal barrier integrity, formulation stability and skin physiology while supporting the pharmaceutical architecture of selected regional formulations.

Its inclusion reflects the SIRIAM principle of integrating highly biocompatible lipid molecules that optimise both formulation performance and dermal compatibility.

Squalane is the fully hydrogenated derivative of squalene, a naturally occurring triterpene that forms an important component of human sebum.

Whereas squalene is highly susceptible to oxidation, hydrogenation converts it into the chemically stable molecule squalane, making it considerably more suitable for pharmaceutical and dermatological formulations.

Modern pharmaceutical-grade Squalane is predominantly obtained from:

sugarcane fermentation;

olive oil;

amaranth seed oil;

other sustainable botanical sources.

Experimental investigations demonstrate multiple biological properties, including:

enhancement of epidermal barrier integrity;

reduction of transepidermal water loss (TEWL);

improvement of skin hydration;

support of epidermal lipid organisation;

reduction of oxidative stress;

improvement of formulation spreadability;

facilitation of dermal delivery of co-formulated lipophilic ingredients.

Unlike many vegetable oils, Squalane closely resembles endogenous human skin lipids and therefore exhibits excellent cutaneous compatibility.

Human clinical studies consistently demonstrate:

improved skin hydration;

enhanced skin softness;

restoration of barrier function;

reduction of xerosis;

excellent cutaneous topical tolerability;

favourable outcomes in sensitive skin.

Although Squalane itself possesses only modest intrinsic anti-inflammatory activity, its ability to restore barrier function indirectly contributes to reduction of epidermal irritation and improved skin resilience.

Current scientific evidence evaluates Squalane primarily as a pharmaceutical emollient and cutaneous topical active ingredient.

No published studies currently investigate Squalane within a region-specific neurodermal formulation architecture comparable to the SIRIAM Platform. Consequently, its inclusion reflects established pharmaceutical properties together with the architectural philosophy of the platform rather than direct evidence for this specific application.

Within the SIRIAM Platform, Squalane functions as both a Regional Signature Component and a multifunctional pharmaceutical lipid.

Its architectural role includes:

optimisation of barrier integrity;

improvement of lipid phase organisation;

enhancement of cutaneous topical acceptability;

support of dermal compatibility;

stabilisation of complex regional formulations.

Future optimisation may refine concentration according to the requirements of individual Regional Master Formulae.